Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19
Ammar Ali Almarzooq
doi: https://doi.org/10.1101/2021.04.24.21256047
Ammar Ali Almarzooq
1Galore Consultancy, Flat 12, Building 144, Road 336, Block 314, Manama, Bahrain
Data Availability
The datasets generated during the current study are included in the supplementary files.
Posted April 27, 2021.
Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19
Ammar Ali Almarzooq
medRxiv 2021.04.24.21256047; doi: https://doi.org/10.1101/2021.04.24.21256047
Subject Area
Subject Areas
- Addiction Medicine (405)
- Allergy and Immunology (716)
- Anesthesia (210)
- Cardiovascular Medicine (2992)
- Dermatology (254)
- Emergency Medicine (447)
- Epidemiology (12881)
- Forensic Medicine (12)
- Gastroenterology (840)
- Genetic and Genomic Medicine (4677)
- Geriatric Medicine (428)
- Health Economics (737)
- Health Informatics (2974)
- Health Policy (1079)
- Hematology (396)
- HIV/AIDS (942)
- Medical Education (434)
- Medical Ethics (116)
- Nephrology (479)
- Neurology (4457)
- Nursing (239)
- Nutrition (654)
- Oncology (2319)
- Ophthalmology (659)
- Orthopedics (261)
- Otolaryngology (330)
- Pain Medicine (289)
- Palliative Medicine (85)
- Pathology (506)
- Pediatrics (1208)
- Primary Care Research (506)
- Public and Global Health (7055)
- Radiology and Imaging (1565)
- Respiratory Medicine (927)
- Rheumatology (447)
- Sports Medicine (389)
- Surgery (495)
- Toxicology (60)
- Transplantation (214)
- Urology (186)